<DOC>
	<DOCNO>NCT00232752</DOCNO>
	<brief_summary>The main objective study assess safety effectiveness sirolimus-eluting Bx VELOCITYTM stent reduce in-lesion late loss patient de novo native coronary artery lesion .</brief_summary>
	<brief_title>Study 4.0mm Sirolimus-Eluting Stent Treatment Patients With Coronary Artery Lesions</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Male nonpregnant female patient minimum 18 year age 2 . Diagnosis angina pectoris define Canadian Cardiovascular Society Classification ( CCS I , II , III , IV ) OR unstable angina pectoris ( Braunwald Classification B &amp; C , III ) OR patient document silent ischemia ; 3 . Target lesion treatable 4mm stent ( visual estimate ) ; 4 . Target lesion 30mm length ( visual estimate ) ; 5 . Target lesion stenosis &gt; 50 % &lt; 100 % ( visual estimate ) ; 1 . Patient experience Qwave nonQwave myocardial infarction document total CK &gt; 2 time normal within precede 24 hour CK CKMB enzymes remain normal time treatment ; 2 . Has unstable angina classified Braunwald III B C , peri infarction ; 3 . Documented Left ventricular ejection fraction 25 % ; 4 . Impaired renal function ( creatinine &gt; 3.0 mg/dl ) time treatment ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>